Expert Advice on Getting CAPA Right

The GMP Letter
Inadequate investigations and corrective and preventive actions have been one of the top reasons for 483 observations since 1997, says James Vesper, president of LearningPlus. A 30-year veteran in the lifesciences business, Vesper talked with FDAnews about how to develop a successful CAPA program to uncover root causes of quality failures.

To View This Article:


Subscribe To The GMP Letter

Buy This Article Now

Add this article to your cart for $40.00